Uses of the drug Lowas 20

Lowas 20 belongs to the group of cardiovascular drugs, the main ingredient is Rosuvastatin 20mg. Lowas 20 is used to reduce total cholesterol, serum triglycerides, ...

Lowas 20 belongs to the group of cardiovascular drugs, the main ingredient is Rosuvastatin (in the form of Rosuvastatin calcium) 20mg. Rosuvastatin is effective in reducing total cholesterol, apolipoprotein B (ApoB), non-HDL-C cholesterol and hypercholesterolemia. In addition, Rosuvastatin also has the effect of lowering triglycerides (TG) and increasing high-density lipoprotein cholesterol (HDL-C).
Lowas 20 is prepared in the form of film-coated tablets and is indicated for use as a dietary supplement in the following cases:
People with primary hypercholesterolemia, mixed dyslipidemia to reduce cholesterol total cholesterol, LDL cholesterol, ApoB, non-HDL-C cholesterol, triglycerides and raised HDL-C. People with increased serum triglycerides. For individuals with homozygous familial hypercholesterolemia, Lowas 20 is used to lower total cholesterol, ApoB, LDL-C as an adjunct to other lipid-lowering therapies or in cases where the patient has been treated with other methods but has not been effective.

Lowas 20 is taken orally and only used when prescribed by a doctor. Patients take the drug with water, can be taken with or without meals. The drug is used only once a day.
The recommended dose of Lowas 20 is to start with the lowest dose. Then, depending on response and need, the doctor will increase the dose in batches, each 4 weeks apart. At the same time, the patient is monitored for the reaction that the drug may cause, especially to the muscle system.
Before treatment with Lowas 20, the patient needs to apply a diet to lower cholesterol and during the course of treatment should continue to maintain this diet.
In the treatment of hypercholesterolemia and mixed dyslipidemia: 5-40mg/time/day, depending on the patient's ability to respond. The recommended initial dose is 10 mg once daily. For patients requiring less effective LDL-C reduction or susceptible to muscle diseases, an initial dose of 5 mg/time/day may be used. For patients with marked hypercholesterolemia (LDL-C above 190mg/dL) may use the initial Lowas 20 dose of 20mg/time/day. For patients who do not meet the LDL-C goal with a dose of 20mg, a dose of 40mg can be used once a day. Patients need to monitor lipid levels for 2-4 weeks after treatment or after increasing the dose to consider appropriate dose adjustment. In the treatment of hypercholesterolemia in homozygous familial patients: The initial dose is 20mg/time/day and the maximum dose is 40mg/time/day. Low dose of Lowas 20 in patients taking cyclosporine: Limit 5mg/time/day. Low dose of Lowas 20 in patients taking protease inhibitors: The maximum dose is 10mg/time/day. Low dose of Lowas 20 as concurrent lipid-lowering therapy: 10 mg once daily in combination with Gemfibrozil. Using higher doses in combination therapy may increase the risk of injury. Low dose of Lowas 20 in people with renal failure, liver failure: People with mild to moderate renal impairment do not need to adjust the dose. Patients with severe renal impairment need to adjust the initial dose is 5mg / time / day and the maximum dose should not exceed 10mg / time / day. Overdose of Lowas 20 drug so far has no specific treatment, patients are mainly treated symptomatically and supportively.

Lowas 20 is well tolerated, so if side effects are present, symptoms are usually mild and transient. Below is the frequency of undesirable effects of Lowas 20 that have been clinically tested in patients taking the drug:
Common: Abdominal pain, nausea, constipation, muscle pain and asthenia. Over 2% of patients taking the drug: Sinusitis, rhinitis, sore throat, headache, nausea, dyspepsia, diarrhea, urinary tract infection, muscle pain, back pain, weakness, flu syndrome. Over 1% of patients taking the drug: Lowas 20 rarely causes periodontal abscess, abdominal pain, vomiting, constipation, flatulence, gastroenteritis, neck pain, chest pain, pelvic pain, arthralgia, arthritis, pathological fractures, anemia, bruises, vasodilation, hypertension, angina pectoris, palpitations, diabetes, peripheral edema, rash, pruritus; dyspnea, pneumonia, asthma, bronchitis, insomnia, dizziness, dizziness, paresthesia, anxiety, asthenia, hypertonia, neuralgia. Lowas 20 rarely causes laboratory abnormalities such as positive proteinuria on the test strip, hematuria (mainly due to high doses), increased levels of creatine, phosphokinase, transaminases, glutamyl, transpeptidase, alkaline phosphatase, bilirubin and thyroid function. Less than 1% of patients taking the drug: Lowas 20 rarely causes cardiac arrhythmias, hepatitis, pancreatitis, hyperglycemia, HbAlC, hypersensitivity reactions such as facial edema, leukopenia, thrombocytopenia, erythema vesicles, urticaria, angioedema, renal failure, photosensitivity, myositis, myasthenia gravis, myopathy, rhabdomyolysis, syncope, cognitive impairment such as confusion and dementia. If there are any abnormal symptoms after taking Lowas 20, the patient should immediately notify the doctor for examination and treatment.

Lowas 20 should not be used in patients with known hypersensitivity to any of its components, in patients with advanced liver disease or in unexplained persistent elevations in serum transaminase levels, or in pregnant or lactating women. Patients with risk factors for muscle damage should be cautious when using Lowas 20 in particular and statin drugs in general because they may experience adverse reactions when using the drug such as myositis, muscle atrophy. Especially the elderly (over 65 years old), people with kidney disease, hypothyroidism. During the course of taking the drug, the patient should be closely monitored to prevent possible adverse reactions. You should tell your doctor immediately if you have symptoms of fatigue, nausea, vomiting, muscle pain, fever, dark urine. Before starting treatment with Lowas 20, patients should have liver function tests or if indicated while taking the drug because the drug can affect liver function, cause biochemical abnormalities of liver function, increase blood levels persistent serum transaminase levels. However, most of them are transient, and after discontinuation of the drug, the condition may improve. Normally, liver enzymes change for about 3 months after taking Lowas 20. Patients with elevated transaminases should be monitored until their condition improves. Reduce dose or discontinue drug if ALT or AST increases more than 3 times the normal value. People who are addicted to alcohol or have a history of liver disease need to be careful when taking the drug. People with risk factors such as old age, kidney failure, hypothyroidism need to be careful when using Lowas 20 because the drug can cause muscle damage such as myopathy. Tell your doctor right away if you have muscle weakness, muscle pain, along with malaise and fever. Discontinue if there is marked increase in creatine kinase or myopathy is suspected or confirmed. In particular, concomitant use of Lowas 20 with cyclosporin or other lipid-lowering agents may increase the risk of myopathy. It is best to avoid taking Lowas 20 in combination with gemfibrozil. Reduce the dose of Lowas 20 in patients with severe myopathy, acute myopathy or at risk of progression to secondary renal failure and rhabdomyolysis. Before treatment with Lowas 20, consider testing for creatine kinase in patients with hypothyroidism, renal impairment, family or personal history of hereditary myopathy or myopathy due to previous statin or fibrate use, who With a history of liver disease and/or alcoholism, the elderly (from 70 years of age) are at increased risk for rhabdomyolysis. Considering the benefits and risks, and closely monitoring the patient, if the creatine kinase test results are more than 5 times the normal value, the drug should not be used. Patients should try to apply a suitable diet, weight loss and exercise to control hypercholesterolemia before taking Lowas 20. Concomitant administration of Lowas 20 with oral contraceptives containing ethinyl estradiol and norgestrel may increase plasma concentrations of oral contraceptives. Concomitant use with other fibrate-lowering agents, niacin (high doses above 1g/day), colchicine may increase the risk of muscle damage. Concomitant use of Lowas 20 with drugs to treat HIV and hepatitis C may increase the risk of muscle damage, especially severe rhabdomyolysis, nephrotic syndrome and lead to renal failure, which can be fatal. death. Above is all information about Lowas 20 drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Lowas 20 for home treatment because there may be unwanted side effects.